Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
August 01 2024 - 5:01PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM 6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
August
2024
Commission
File Number: 001-38723
Tiziana
Life Sciences LTD
(Exact
Name of Registrant as Specified in Its Charter)
9th Floor
107
Cheapside
London
EC2V
6DN
(Address
of registrant’s principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION
CONTAINED IN THIS REPORT ON FORM 6-K
On
July 26, 2024, Tiziana Life Sciences Ltd. (the “Company”) accepted the voluntary resignation of Matthew W Davis, MD, RPh
as Chief Operating Officer and Chief Medical Officer, effective as of August 2, 2024. Dr. Davis resigned for personal reasons, and his
resignation is not related to any disagreement with the Company on any matter relating to the Company’s operations, policies, or
practices. The Company will make a further announcement regarding Dr. Davis’ replacement once the search process is complete.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
TIZIANA LIFE SCIENCES LTD |
|
|
|
|
Date: August 1, 2024 |
By: |
/s/
Keeren Shah |
|
|
Name: |
Keeren Shah |
|
|
Title: |
Chief Financial Officer |
2
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Historical Stock Chart
From Aug 2023 to Aug 2024